ClinicalTrials.gg
Not yet recruitingNCT07951086Updated Nov 20, 2026

A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Rheumatoid Arthritis

A Phase 2 interventional study of DDY391 and Placebo in Rheumatoid Arthritis, sponsored by Novartis Pharmaceuticals. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 31 studies in Arthritis, Rheumatoid by Novartis — 2 open to participants now, 5 under way, none of them phase 3. Arthritis, Rheumatoid · Novartis.

Planned enrollment
16th of 31
96 · median 96
Started
2027
the only one that year
Phase 2
10 of 31
1 open now
Registered
31st of 31
by date

Among the 31 studies in Arthritis, Rheumatoid by Novartis, this one is the 16th largest by planned enrollment, is the only one that started in 2027, is one of 10 in phase 2, and was the 31st registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 31 studies in Arthritis, Rheumatoid by Novartis are open now. Recruiting first, the newest first:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Arthritis, Rheumatoid by Novartis, or all of them as a file.
02

Study summary

The purpose of this Phase 2 study is:

  1. to evaluate the efficacy, safety and tolerability of DDY391 in participants with moderate to severe active rheumatoid arthritis (RA).
  2. to provide information about dose selection and study design for subsequent clinical development.
Read the detailed description

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of DDY391 in adult participants with active moderate to severe rheumatoid arthritis. The study will enroll participants with an inadequate response (IR) and/or intolerance (INT) to 1-2 bDMARD, with different mechanisms of action (MoA), or with IR or INT to one prior JAKi.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid arthritis
  • DDY391
  • VAV1
  • bDMARD
  • JAKi
  • ACR50
  • autoimmune disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of RA for at least 6 months prior to screening according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria.
  • Moderate to severe RA at screening.
  • Participants must be a rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibody (anti-CCP) positive at screening as assessed by central laboratory.

Key Exclusion Criteria:

  • Presence of inflammatory conditions other than RA including but not limited to those associated with arthralgia or arthritis (e.g., psoriatic arthritis, systemic lupus erythematosus, scleroderma, sarcoidosis) or presence of active fibromyalgia or osteoarthritis with articular symptoms.
  • Participants with ACR functional class IV.
  • Previous treatment with any direct cell-depleting therapies, including but not limited to anti-CD20, unless ≥ 12 months prior to baseline.
  • History of lymphoproliferative disease or any known or history of malignancy of any organ system within the past 5 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
  • Active viral, bacterial or other infections requiring systemic treatment at the time of screening or randomization, or history of recurrent infection or of recurrent bacterial infections.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    DDY391 - Dose A

    Participants will receive DDY391 Dose A.

    Drug: DDY391

  • Experimental
    DDY391 - Dose B

    Participants will receive DDY391 Dose B.

    Drug: DDY391

  • Experimental
    Placebo

    Participants will receive matching placebo.

    Drug: Placebo

Interventions

  • DrugDDY391

    DDY391

  • DrugPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Number of participants achieving American College of Rheumatology 50 (ACR50) response

    To evaluate the efficacy of DDY391 versus placebo through achievement of ACR 50.

    Time frame: Week 12

Secondary outcomes

  1. Change from baseline in disease activity score 28 C-reactive protein (DAS28-CRP)

    To evaluate the efficacy of DDY391 versus placebo through DAS28 CRP.

    Time frame: Week 12

  2. Incidence and severity of treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.

    Time frame: through Week 16

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for May 2028, 15 months later.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's planned 15 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Jan 26, 2027
Primary completionEst.
May 18, 2028
CompletionEst.
Jun 15, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951086
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Jan 26, 2027 (estimated)
Primary completion
May 18, 2028 (estimated)
Completion
Jun 15, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DDY391

Start the discussion